The global multiple sclerosis drugs market size was valued at USD 27.37 billion in 2025 and is projected to grow from USD 28.38 billion in 2026 to USD 37.95 billion by 2034 at a CAGR of 3.7% during the forecast period 2026-2034. North America dominated the multiple sclerosis drugs market with a market share of 42.6% in 2025.
Multiple sclerosis (MS) is a chronic, autoimmune, and inflammatory disorder that affects the CNS and the communication between different parts of the body and the brain, resulting in various symptoms, including vision loss, pain, fatigue, and impaired coordination. Globally, the prevalence of MS is rising at a concerning rate. As per the National Multiple Sclerosis Society, around 2.3 million people are suffering from MS across the globe, and the number is expected to surge in the years to come, increasing the demand for innovative MS drug discovery with enhanced efficacy and reduced adverse effects. Furthermore, reimbursement plays a vital role in the growth of the market, as MS drugs are expensive. Without reimbursement, the treatment may become unaffordable for most MS patients across the globe.
Download a Free Sample To learn more about this report,
Long-Acting Treatments Make MS Management More Convenient
The multiple sclerosis drugs market is moving toward treatments that can provide sustained disease control while making long-term therapy easier for patients. Disease-modifying therapies are increasingly available in oral, injectable, and infusion forms, giving neurologists more options based on disease activity, treatment response, and patient needs. The continued focus on reducing relapses and slowing disability progression is supporting the multiple sclerosis drugs market growth as treatment strategies become more personalized.
Safety Monitoring Becomes More Important in MS Treatment
As patients may remain on MS therapies for many years, healthcare providers are paying closer attention to treatment safety and long-term monitoring. Regulators are continuing to review safety information and update prescribing guidance when new risks emerge. This focus is shaping prescribing decisions and encouraging drug manufacturers to develop therapies with improved safety and tolerability profiles, contributing to the increasing multiple sclerosis drugs market size.
Growing Need for Disease-Modifying Treatments and More Convenient Therapies
The market is supported by the continuing need for treatments that reduce relapses, slow disease progression, and control disease activity in people with multiple sclerosis. The treatment landscape includes oral medicines, injectable therapies, infusions, and newer targeted approaches. Greater attention to earlier treatment, personalized care, and convenient dosing is encouraging pharmaceutical companies to develop therapies that are easier for patients to use while maintaining disease control. These developments are strengthening multiple sclerosis drugs market demand.
High Treatment Costs and Long-Term Therapy Requirements
The market faces pressure from the high cost of many disease-modifying therapies, particularly biologic treatments and advanced infusion therapies. Multiple sclerosis is a chronic condition, so patients may require treatment and monitoring for many years. This creates a substantial financial burden for healthcare systems and patients, especially where reimbursement is limited. Safety monitoring and treatment-related adverse effects can add further costs.
Expansion of Oral Therapies and Earlier Disease Management
The market has significant opportunities in oral therapies, targeted immunomodulators, and treatments designed to address different stages and forms of MS. Easier administration can improve treatment convenience and potentially support adherence compared with therapies requiring frequent injections or visits to infusion centers. Continued research into disease mechanisms and biomarkers is also creating opportunities for more personalized treatment strategies. These developments are shaping important multiple sclerosis drugs market trends.
Addressing Disease Progression and Maintaining Long-Term Treatment Response
The market continues to face the challenge of developing therapies that can effectively control MS over the long term while minimizing adverse effects. Although existing disease-modifying treatments can reduce relapse activity, patients can respond differently to therapy, and some may continue to experience disability progression. Developing treatments that address progressive forms of MS remains particularly important.
Request Customizationto receive a tailored report.
Immunomodulators Segment Dominated the Multiple Sclerosis Drugs Market with a 38.7% Share in 2025
The immunomodulators segment dominated the global multiple sclerosis drugs market with a 38.7% share in 2025, representing approximately $10.59 billion. These medicines help modify abnormal immune activity involved in multiple sclerosis and are widely used to reduce disease activity and the frequency of relapses. Growing emphasis on early treatment, improved disease monitoring, and the availability of disease-modifying therapies continues to support demand for immunomodulators.
Immunosuppressants accounted for 26.4% of the market, followed by interferons at 22.8%. These therapies remain important options for managing disease activity, particularly among patients requiring long-term treatment. Other drug classes represented 12.1% and include newer or more specialized treatment approaches. Continued development of therapies with improved efficacy, tolerability, and patient convenience is expected to support competition across drug classes.
Oral Segment is Projected to Register the Fastest Growth in the Multiple Sclerosis Drugs Market at a CAGR of 6.38%
The oral segment is projected to register the fastest growth in the multiple sclerosis drugs market at a CAGR of 6.38% during 2026–2034, supported by the convenience of self-administration and the growing preference for treatments that can be taken at home. Oral therapies can reduce the burden associated with injections and may make long-term treatment easier for some patients. Continued development of oral disease-modifying therapies is expected to expand treatment options for people living with multiple sclerosis.
Injectable therapies accounted for 34.6% of the market and remain an important treatment route because several established multiple sclerosis medicines are administered through injections. Intravenous treatments, including infusion-based therapies, continue to be used for patients requiring medicines delivered directly into the bloodstream. Intramuscular and subcutaneous administration also remain relevant, providing different options depending on the drug, treatment schedule, and clinical requirements.
Hospital Pharmacy Segment Dominated the Multiple Sclerosis Drugs Market with a 49.2% Share in 2025
The hospital pharmacy segment dominated the global multiple sclerosis drugs market with a 49.2% share in 2025, representing approximately $13.47 billion. Hospital pharmacies play an important role in supplying specialized medicines, particularly for patients receiving treatment under the supervision of neurologists and other healthcare professionals. They also support medication management, treatment monitoring, and access to therapies that may require clinical administration or specialist oversight.
Retail pharmacies accounted for 36.5% of the market and remain an important channel for patients receiving prescriptions for ongoing multiple sclerosis treatment. Online stores represented 14.3% and are gaining attention as digital healthcare services and home delivery become more widely used. The expansion of specialty pharmacy services and improvements in medication delivery are also helping patients access long-term therapies more conveniently.
Primary-Progressive Multiple Sclerosis (PPMS) Segment is Projected to Register the Fastest Growth at a CAGR of 6.18%
The primary-progressive multiple sclerosis (PPMS) segment is projected to register the fastest growth in the multiple sclerosis drugs market at a CAGR of 6.18% during 2026–2034. PPMS is characterized by a gradual worsening of neurological function rather than distinct periods of relapse and recovery. Increasing recognition of progressive forms of multiple sclerosis and the development of therapies specifically addressing disease progression are contributing to greater clinical attention and treatment demand in this segment.
Relapsing-remitting multiple sclerosis (RRMS) accounted for the largest share at 68.4%, representing approximately $18.72 billion. RRMS remains the most common form of MS and is characterized by periods of new or worsening symptoms followed by periods of recovery. Secondary-progressive MS (SPMS) accounted for 15.6%, while progressive-relapsing MS (PRMS) represented 4.3%. Continued advances in disease-modifying treatments and greater emphasis on early diagnosis and long-term disease management are supporting treatment across these disease categories.
Speak to an Analystto discuss market opportunities.
North America is leading the global multiple sclerosis drugs market share. The rising number of hospitalization procedures, increasing prevalence of MS, expanding healthcare infrastructure, and surging healthcare expenditure in the U.S. and Canada are driving the market growth. The rising concentration of pharmaceutical companies in R&D activities for developing novel drugs for treating MS is driving the market growth. As per the Institute for Clinical and Economic Review (ICER), the U.S. spends around USD 28,000 million annually for the treatment of MS. The reimbursement programs in the U.S. and Canada are raising the adoption of the treatment. According to the National Multiple Sclerosis Society, around 291 per 100,000 people in Canada are suffering from MS. Whereas, in the U.S., 450,000 people are suffering from MS. Additionally, the National Multiple Sclerosis Society (NMSS) and Multiple Sclerosis Association of America (MSAA), are actively engaged in educating people regarding the symptoms and advanced treatments for MS. Similarly, the leading players are actively working in the field to attend to the existence of strong unmet needs in the clinical segment and the rising demand for highly effective and rapidly acting medications. The U.S. is the biggest market for firms such as Biogen, Novartis AG, and Sanofi SA, further boosting the market growth.
Europe is predicted to be the second in the global multiple sclerosis drugs market on account of the increasing prevalence of MS. As per the European Multiple Sclerosis Platform (EMSP), over 600,000 people are living with MS in Europe. The market is driven by rising government support, increasing healthcare expenditure on MS, surging investments in R&D of MS drugs and clinical studies, and rising awareness regarding advanced treatment options. The United Kingdom is anticipated to hold a sizeable proportion of the multiple sclerosis medicine market over the projection period. The growing elderly population, rising healthcare expenditures, and increasing research and development activities contribute to market expansion. On the other hand, rising nations in the region, such as France, Italy, and Spain, are anticipated to grow at a promising rate during the forecast period.
In Asia Pacific, the multiple sclerosis drugs market is majorly driven by a large pool of patients suffering from MS in China and Japan, the launch and approval of new products, and growing investments by leading market players. The governments are actively working to develop the healthcare infrastructure and are increasing their healthcare expenditure for the same. Additionally, leading players in the region are engaging in agreements with local drug manufacturers to develop technologically advanced products. Moreover, the well-improved distribution network in pharma-emerging nations is also supporting the regional market.
The Middle East and Africa are expected to witness sluggish growth in the multiple sclerosis drugs market. In Africa, lack of knowledge regarding the treatment options for MS, the high cost of drugs, and less development in medical facilities are the factors hampering the market growth. However, the increasing prevalence of MS will create lucrative opportunities for the market in the years to come. The Middle East North Africa Committee for Research and Treatment in Multiple Sclerosis (MENACTRIMS) is actively working to provide education regarding the symptoms, treatment, and effects of MS. Due to the increasing incidence of the disease in Latin America, the government has been compelled to develop preventative measures in the form of guidelines and recommendations. In addition, government agencies are undertaking several public awareness efforts to educate patients about the various possible treatment alternatives. In addition, as per capita health expenditures increase, product demand will increase, increasing the growth of the Latin American market for multiple sclerosis drugs. However, the high cost of multiple sclerosis treatments would have a negative impact on the growth rate of multiple sclerosis drugs over the projection period.
Unlock Regional Insightsto access country-level data, & regional trends.
Customize This Report to Match Your Strategic Objectives
Author's Details
Research Associate
Mitiksha Koul is a Research Associate with 2 years of experience in market research. She focuses on analyzing industry trends, competitive landscapes, and growth opportunities to support strategic decision-making. Mitiksha’s strong analytical skills and research expertise enable her to deliver actionable insights that help businesses adapt to evolving market dynamics and achieve sustainable growth.
We are featured on:
sales@straitsresearch.com